Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 177-184

  Cui, Yimin ^a   Song, Yan ^b   Wang, Jessie ^b   Yu, Zhigang ^b   Schuster, Alan ^b   Barrett, Yu Chen ^b   Frost, Charles ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apixaban; Factor Xa inhibitor; Oral anticoagulant; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; APIXABAN; BLOOD CLOTTING FACTOR 10A; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

EID: 84889688233     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S51981     Document Type: Article

References (25)

1. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
2. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807-815.
3. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.
4. Granger CB, Alexander JH, McMurray JJ, et al Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365: 981-992.
5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
6. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.
7. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.
8. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol. 2010;105:629-632.
9. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn. 2010;37:3-24.
10. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006;79:197-205.
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Ethnic factors in the acceptability of foreign clinical data-E5 (R1). 1998. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/ E5_R1__Guideline.pdf. Accessed October 3, 2013.
12. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-1271.
13. Frost C, Nepal S, Barrett Y, LaCreta F. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost. 2009;7:PP-MO-407.
14. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
15. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75: 476-487.
16. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. Epub March 4, 2013.
17. Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41:906-915.
18. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]. J Clin Pharmacol. 2008;48:1132.
19. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448-458.
20. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37:1738-1748.
21. Zhang D, He K, Herbst J, et al. Characterization of transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41:827-835.
22. Yamahira N, Imai Y, Wastall P, et al. A placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese subjects (A637). Can J Clin Pharmacol. 2008;15:e719.
23. Yu Z, Nepal S, Bragat A, Shenker A, Frost C. Single dose apixaban pharmacokinetics and pharmacodynamics in healthy male Japanese and Caucasian subjects (A647). Can J Clin Pharmacol. 2008;15:e724.
24. Zhang D, He K, Raghavan N, et al. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis. 2010;29:70-80.
25. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012;107:916-924.